Toll Free: 1-888-928-9744

RNAi

Published: Apr, 2015 | Pages: 1147 | Publisher: RESEARCH IMPACT TECHNOLOGIES
Industry: Biotechnology | Report Format: Electronic (PDF)

This report covers both products and services in the RNAi industry. The global RNAi market is analyzed by Tools/Products and Applications for each of the geographic regions- North America, Europe, Asia-Pacific and Rest of World. The RNAi Tools/Products are further segmented into Design/Software (miRNA Target Scan, miRNA Analysis Software, and Design Software), Synthesis (Expression Vectors, Chemical, miRNA Isolation, Dicer/RNAseIII, and In Vitro), Delivery (Vector Based, Transfection Reagents, and Electroporation), Monitoring/Optimizing (Primers for RTqPCR, Controls, and miRNA Detection Tools), and Libraries (Human, Mouse, and Rat). Application by Research (Functional Genomics, Metabolism, and Protein Chemistry), Therapeutics (Oncology, Neurology, Ophthalmology, and Virology) and Drug Development (Target Identification, Target Validation, and Drug Mechanism) are also analyzed. Business profiles of major companies are discussed in the report. The report serves as a guide to global RNAi industry covering 280 plus companies that are engaged in RNAi synthesis, R&D, therapeutics, test kits, tools and services. Major Research Organizations and Universities serving the industry are also covered in the Corporate Directory section of this report. Information related to recent product releases, product developments, partnerships, collaborations, mergers and acquisitions, ethical issues, regulatory affairs, and other areas of concern is also covered in the report. Estimations and predictions are provided by geographic regions with exclusive graphical representations illustrated for 485 plus exhibits.
 Table of Contents

I. SCOPE AND METHODOLOGY	1
II. REPORT SYNOPSIS	3
Introduction to RNAi	3
RNAi - Nature’s Way of Silencing Gene	3
Definition	4
Summary	4
RNAi – The Main Objectives of Our Study	5
RNAi – Some Basics	5
History of RNAi	7
RNAi – Origins and Discovery	8
Segmentation of RNAi	10
Exhibit 1. Segmentation of Global RNAi Market by Application and Tools/Products	10
Exhibit 2. Segmentation by Application	10
Exhibit 3. Segmentation by Tools/Products	10
Facts About RNAi	11
Relation between siRNA Length and siRNA Function	18
Functional Significance of siRNA Length	18
Is siRNA Length Influential of siRNA Function?	19
Use of RNAi in Mammalian Systems	19
RNAi - Global Market Analysis	22
Exhibit 4. RNAi– Global Market Estimations & Predictions (2005 -2020) in US$ Million	22
Exhibit 5. List of Major RNAi Global Companies	23
III. MARKET DYNAMICS	24
Global RNAi Market Overview	24
RNAi - A Breakthrough in Molecular Biology	24
Nobel Prize	24
RNAi – Gene Silencing Mechanism	24
esiRNA Technology	26
RNAi – The Corporate Scenario	26
RNAi – The Commercial Potential	28
RNAi – The Pharma Perspective	31
RNAi – Unlike Stem Cell Therapy	31
Global RNAi Market	32
Exhibit 6. RNAi – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	32
Exhibit 7. RNAi – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	33
North America RNAi Market	34
Exhibit 8. RNAi – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	34
Exhibit 9. RNAi – North American Market Shares (2010, 2015 & 2020) for United States and Canada	35
United States RNAi Market	35
Canadian RNAi Market	35
Exhibit 10. List of Major RNAi Companies in North America	35
European RNAi Market	37
Exhibit 11. RNAi – European Market Estimations & Predictions (2005 - 2020) by Geographic Region for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	37
Exhibit 12. RNAi – EuropeanMarket Shares (2010, 2015 & 2020) by Geographic Region for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	38
German RNAi Market	39
United Kingdom RNAi Market	39
Belgian RNAi Market	39
French RNAi Market	39
Russian RNAi Market	39
Exhibit 13. List of Major European RNAi Companies	39
Asia-Pacific RNAi Market	40
Exhibit 14. RNAi –Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	40
Exhibit 15. RNAi – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	41
Australian RNAi Market	41
Japanese RNAi Market	41
China RNAi Market	41
Indian RNAi Market	41
South Korean RNAi Market	41
Exhibit 16. List of Major Asia-Pacific RNAi Companies	42
Rest of World RNAi Market	43
Exhibit 17. RNAi – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries in US$ Million	43
Exhibit 18. RNAi – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries in US$ Million	44
Brazilian RNAi Market	44
Israeli RNAi Market	44
South African RNAi Market	44
Exhibit 19. List of Major Rest of World RNAi Companies	44
RNAi - Market Trends	45
RNAi – An Emerging Class of Drugs in Pharmaceuticals	45
Biotech/Pharma Industry’s Interest in RNAi	45
RNAi’s Functionality	45
Sourcing and Market Potential	45
Marketing Strategy	45
Economic Possibilities	45
Mission Ahead for RNAi	46
Biotech Companies Realize to Gain Billions of Dollars by Applying RNAi Technology	47
RNAi: Focus on Modeling Cellular Systems	49
Initial Stages of Mammalian RNAi Screening	50
Development of Signaling Pathways Using a Mammalian RNAi Screen	53
Identification of Components in a Biological Process: RNA interference	53
Component Discovery	53
Reporter Assays and High-Content Image-based Screening	54
Component Validation and Classification	55
An Outlook on Binary Genetic Interactions with RNAi	58
Hypothetical RNAi Screening for Cell-Growth Regulators	59
Prospects of Knockdown Technology	60
RNA interference (RNAi)	61
Introduction	61
Redefinition of RNA	61
Knockdown of Genes	62
RNAi on a Large Scale	63
RNAi: Beyond Machinery	63
Silencing Diseases	64
Principle Behind RNAi	65
Delivery	66
Area of Concern	67
Major Companies in RNAi Industry	68
Allele Biotechnology and Pharmaceuticals, Inc. (USA)	68
Alnylam Pharmaceuticals, Inc. (USA)	68
Arrowhead Research Corporation (USA)	71
Asuragen, Inc. (USA)	72
Benitec Ltd. (Australia)	74
Bioneer Corporation (South Korea)	75
Cenix Bioscience GmbH (Germany)	76
Cepheid (USA)	78
Clontech Laboratories, Inc. (USA)	78
CytoPathfinder, Inc. (Japan)	79
GlaxoSmithKline PLC (UK)	80
InvivoGen (USA)	81
Life Technologies Corporation (USA)	81
Marina Biotech, Inc. (USA)	84
Mirus Bio LLC (USA)	85
Novus Biologicals, LLC (USA)	85
Promega Corporation (USA)	86
Qiagen N.V (The Netherlands)	87
Quark Pharmaceuticals, Inc. (USA)	87
Regulus Therapeutics, Inc. (USA)	89
Rosetta Genomics Laboratories (Israel)	90
RXi Pharmaceuticals Corporation (USA)	91
Silence Therapeutics plc (UK)	92
SomaGenics, Inc. (USA)	93
Sylentis SA (France)	94
Tekmira Pharmaceuticals Corporation (Canada)	95
Major Activities in RNAi Market	96
Cenix BioScience Enters into Research Service Agreement with Bayer Pharma AG	96
Rosetta Genomics and Marina Biotech Enters into Strategic Collaboration	96
Alnylam Completes Acquisition of Sirna Therapeutics	96
Rosetta Genomics Enters into Collaboration with Rabin Medical Center of Clalit Health Services for microRNA-Based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation	97
Regulus Renews Strategic Alliance with Sanofi	97
InteRNA Technologies, UCB and University of Bonn Enters into Collaboration to Study the Role of microRNAs in Neurodegenerative Diseases	98
Tekmira Enters into Development Agreement on Delivery Technology for Agricultural Applications	98
Alnylam Establishes Transformational Alliance with Genzyme to Develop and Commercialize RNAi Therapeutics as Genetic Medicines	98
Marina Biotech and Mirna Therapeutics Revises microRNA-based Therapeutics License Agreement	99
Rosetta Genomics Enters into Master Service Provider Agreement with a Major International Biopharmaceutical Company	99
Rosetta Genomics Includes Romania and Turkey to Expand microRNA Cancer Testing Services Distribution Agreement with GeneKor	100
Rosetta Genomics Enters into Sponsored Research Agreement with Ramot at Tel Aviv University	100
Collaboration between MultiCell Technologies and Genisphere for Targeted Delivery of MCT- 485, a Noncoding miRNA to Treat Cancer	100
Servier Expands Strategic Alliance with miRagen Therapeutics	101
Cenix BioScience Enters into Collaboration with Debiopharm for Identification of Predictive Biomarkers	101
Santaris Pharma Enters into Discovery Collaboration with Bristol-Myers Squibb for RNA-targeted Medicines	101
miRagen Therapeutics Obtains Exclusive License to Intellectual Property from the University of Glasgow	101
Benitec Biopharma Out-Licenses RNAi Technology to Regen	102
Arcturus Therapeutic Takes Over Marina’s UNA Patent Estate	102
Thermo Fisher Scientific Plans to Acquire Life Technologies Corporation	102
Medicines Company Enters into a RNAi Therapeutics Partnership with Alnylam	103
Santaris Pharma A/S and miRagen Therapeutics Expands Global Strategic Partnership	104
Benitec Acquires Tacere Therapeutics	104
Syngenta Acquires Devgen	104
Silence Therapeutics Signs Contract with MiReven Pty Ltd.	105
Regulus Therapeutics Enters into Collaboration with AstraZeneca	105
Alnylam Receives Payment from GlaxoSmithKline in the VaxiRNA Partnership	105
Alnylam and Ascletis Enters into Partnership to Develop ALN-VSP	106
Genisphere and LIMR Extends Partnership on miRNA Biomarker Development	106
Alnylam and Ascletis Enters into Partnership to Develop ALN-VSP	106
Quark Pharmaceuticals and Silence Therapeutics Extends Contract with Pfizer to Develop Silence’s AtuRNAi in a Novel Indication	107
Alnylam and PBL Signs License Agreement for Baulcombe and Hamilton RNAi Patent	107
Calimmune Out-Licenses ddRNAi Technology to Benitec Biopharma Signs	108
Bachem and BioSpring Team Up to Develop Oligonucleotide Peptide Conjugates for R&D	108
Arrowhead Research Corporation and Axolabs GmbH Signs Strategic Alliance and Master Services Agreement for RNAi Therapeutics	108
Cenix BioScience Expands Operations in the United States	108
OPKO Health Acquires CURNA Inc.	109
Alnylam and Arrowhead Enters into Collaboration and Licensing Agreement	109
Marina Biotech Signs License Agreement with Mirna Therapeutics for Development of microRNA-based Therapeutics	109
Genisphere Out-Licenses RNA Amplification and MicroRNA Labeling Technologies to Affymetrix	110
Benitec Plans to Develop Gene Therapy for Oculopharyngeal Muscular Dystrophy	110
Cenix Signs Agreement with SYGNIS for Developing RNAi Research	110
Affymetrix and Genisphere Sign Strategic Licensing Agreement for Proprietary MicroRNA Reagents	110
Alnylam and GSK Collaborates on RNAi Technology for Vaccine Production	111
Arrowhead Research Acquires Roche RNA Assets and Research Site	111
Rosetta Genomics Collaborates with Avatao Biotech for the Marketing of miRview Tests in China	112
Servier and Miragen Collaborates in a US$ 352 Million Deal for MicroRNA-targeting Drugs	112
Silence Therapeutics Signs Agreement with Mirna Therapeutics for the Evaluation of Delivery of New microRNA Therapeutics	112
Tekmira Secures Global Exclusive License to Novel RNAi Platform	113
Tekmira in association with Bristol-Myers Squibb Expands Collaboration to include Broader Applications of LNP Technology	113
Cenix BioScience Enters into Collaboration and Technology License Agreement for In Vivo siRNA Delivery	113
Precision NanoSystems and Alnylam Forms New Delivery Collaboration	114
AlCana Technologies, The University of British Columbia, and Alnylam Extend Delivery Research Collaboration	114
Marina Biotech Plans to Co-Develops and Co-Commercializes RNAi based Therapies for Bladder Cancer treatment with Debiopharm	114
AVI BioPharma Alliances with Karolinska Institutet to Detect RNA-based Therapeutic Candidates for XDR-TB treatment	115
Silence Therapeutics and miRagen Therapeutics Signs Agreement for the Evaluation of Delivery of Novel microRNA-based Therapeutics	115
Alnylam, Medtronic, & CHDI Foundation in Collaboration to Advance RNAi Therapy to Treat Huntington's Disease	115
Quark Signs Licensing Option Agreement with Novartis for p53 Suppressor Drug QPI-1002	116
Nitto Denko Inks Collaboration Agreement with Quark to Develop a new siRNA Anti-fibrotic Drug	116
Santaris Pharma and miRagen Therapeutics Collaborate for Developing microRNA-targeted Medicines	116
Sanofi-Aventis and Regulus in Major Strategic Alliance on microRNA Therapies	117
Royal Philips Signs Research Agreement with RXi to Undertake Joint Research on Novel Image-Guided Therapy Concepts based on RNAi	117
siRNA Delivery Collaboration between Silence Therapeutics and AstraZeneca Extended	118
MDRNA Buys Cequent Pharmaceuticals	118
Silence Therapeutics Expands siRNA Delivery Collaboration Dainippon Sumitomo	118
Collaboration between GSK and Isis Pharmaceuticals for RNA Therapeutics to Counteract Rare and Infectious Diseases	118
MDRNA Gains BNA Patents for Widening the RNAi-Drug Discovery Platform	119
Regulus Therapeutics and GSK Establishes New Collaboration for Development and Commercialization of microRNA Therapeutics Targeting miR-122	119
MDRNA Extends Collaboration with VPC for Expanding the Bladder Cancer Program	119
Alnylam and Roche Advance RNAi Therapeutic Collaboration Phase of Landmark 2007 Alliance	120
Alnylam and KOKEN Enters into Licensing Agreement for Kreutzer-Limmer Patents	120
AXA Diagnostics Procures Italian Marketing Rights to Rosetta Genomics’ Diagnostics Tests	120
Santaris Pharma A/S Collaborates with Shire plc for Developing RNA-based Medicines	120
Alnylam Extends RNAi Therapeutics Collaboration with Novartis	121
Eurogentec Establishes New Facility for Oligo Synthesis	121
Isis and Alnylam in New Collaboration for Development of Single-Stranded RNAi Technology	121
MDRNA Inks a Licensing Agreement with Novartis for RNAi Delivery Technology	122
Cenix BioScience Collaborates with Boehringer Ingelheim for developing RNAi based Target Discovery Technology	122
Alnylam and Cubist Forms Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting RSV Infection	122
Alnylam Forms Collaboration with UCSF to Investigate Therapeutic Silencing of Key Gene Implicated in Uveal Melanoma	123
Affymetrix Acquires Panomics	123
Thermo Collaborates with Genentech for Development of siRNA Therapeutics	123
Alnylam Enters into Collaboration with Max Planck Institute	124
Roche Buys Mirus to Reinforce Study on RNAi Delivery	124
Thermo Fisher Scientific Buys Open Biosystems, Creating Unmatched RNAi Platform	124
Alnylam and Kyowa Hakko Collaborates to Develop and Commercialize ALN-RSV01 in Asia	125
Alnylam and Takeda Enters into Alliance for RNAi Therapeutics	125
Rosetta Inks Agreement with West Coast CLIA Certified Lab for Developing and Validating Tests	125
Asuragen Establishes New Company, Mirna Therapeutics	125
GlaxoSmithKline Enters Into Partnership Agreement with Regulus To Develop microRNA Targeted Therapeutics for Inflammatory Diseases treatment	126
Silence Therapeutics Enters into Agreement with AstraZeneca for the Development of Novel Approaches for siRNA Drug Delivery	126
Nastech Pharmaceutical Allocates its RNA-based Intellectual Property to its Subsidiary	127
RXi Pharmaceuticals Acquires Exclusive Rights to RNAi Sequences to Genes	127
Columbia University Medical Center and Rosetta Genomics in Development Collaboration	127
Asuragen Offers Newly Developed microRNA Services	127
Invitrogen Corp. and RXi Pharmaceuticals in Collaboration Agreement for Enhancement of RNAi Technology…	128
Exiqon’s Locked Nucleic Acids Licensed to Applied Biosystems	128
New Series of siRNA Developed by Applied Biosystems	128
Thermo Fisher Scientific and Lentigen Collaboration for Technology Development	128
Universite de Montreal to Study RNAi through Collaboration with Sigma-Aldrich	129
Isis and Alnylam Join Hands to Establish Regulus Therapeutics	129
RNAi Center Funding in Massachusetts	129
Silence Therapeutics Enters into Partnership with AstraZeneca	129
RXi Pharma Signs License Agreement with Cold Spring Harbor Laboratory	130
Two-Year Agreement between Mirus Bio and Pfizer for Evaluation of RNAi Delivery Technology	130
RXi Pharma Receives RNAi Assets from Parent Company	130
Applied Biosystems Launches the StepOne™ Real-Time PCR System	130
Nastech Acquires Exclusive Rights to RNAi Intellectual Property and Technology	131
Artemis Enters into Deal with Merck for Production of RNAi Mouse Models	131
Senetek Enters into Agreement with Poland’s IBCPAS for Treating Brain Tumors	131
Merck Buys Entire Stake in Sirna Therapeutics	132
Joint Effort to make a New Facility for Proteomics Profiling and Drug Effects in Human Cells	132
Framework Agreement signed Between Cenix BioScience and Merck KGaA	133
Invitrogen Launches Advanced Transfection Reagents	133
Calando Picks Agilent for siRNA production	133
Alnylam Receives Biodefense Contract worth US$ 23 million from Government Agency…	134
Bio-Rad Enters into Alliance with Integrated DNA Technologies for Developing RNAi…	134
Dharmacon Associates with Amaxa for Improved Delivery of siRNA into Complex Cell Types…	134
QIAGEN Enters into Alliance with CytoPathfinder for developing novel equipments for high-throughput RNAi screening…	134
Sirna Signs an Agreement with GSK for Developing RNAi based Drugs for Respiratory Disease Treatment….	135
Applied Biosystems Acquires Complete Stake in the Ambion’s Research Products Division…	135
Nastech Acquires Galenea along with Galenea’s IP and Technology Rights …	135
Ambion Enters into Alliance with GE Healthcare for Reinforcing the study on Micro-RNA Microarray…	136
Non-Exclusive License Agreement Signed Between Alnylam Pharma and Eurogentec	136
Ambion Furnishes Cepheid with Licenses of Armored RNA…	136
Ambion Extends Partnership with Wyeth for the Development and Supply of RNA…	137
Major Product Innovations/Launches in RNAi Market	138
Exiqon Introduces LNA™ microRNA Mimics with No Off-target Effect	138
AstraZeneca Selects a New Pre-Clinically Validated microRNA Oncology Target	138
FDA Grants Additional Orphan Drug Status to ALN-AT3, an RNAi Therapeutic Product of Alnylam to Treat Hemophilia	138
Israeli Office of the Chief Scientist Funds Rosetta Genomics and Ramot Tel Aviv University’s Development of microRNA Oncology Therapy	139
Alnylam Attains Additional Orphan Drug Status for ALN-AT3, an RNAi Therapeutic from U.S. FDA for the Treatment of Hemophilia	139
Arrowhead Initiates Phase I Trial of RNAi Therapeutic - ARC-520 for Chronic Hepatitis B Infection Treatment	139
Alnylam Releases Positive Superior Outcome for ALN-TTRsc for Treating TTR-Mediated Amyloidosis	140
Dicerna Added Patent Claims Widening Coverage of Extended Dicer Substrate Therapeutic Structures	140
Alnylam Releases Novel Pre-clinical Data on ALN-AT3, for the Treatment of Hemophilia and Rare Bleeding Disorders	140
Alnylam Presents Positive Phase II Data for ALN-TTR02, for TTR-Mediated Amyloidosis (ATTR) Treatment	141
Alnylam Scientists Reports Pre-Clinical Findings with ALN	141
EGEN Reports Positive Results from the Rat Model of Pulmonary Arterial Hypertension (PAH) Study	141
Arrowhead Gains Patent Allowance for DPC siRNA Delivery System including Peptide Backbone	141
Dicerna Receives First Patent in Japan Related to Dicer Substrate siRNA Molecules	142
Arrowhead RNAi Candidate ARC-520 exhibits over 90% decrease in Circulating HBV DNA in Chimpanzee with Chronic Hepatitis B	142
Dicerna Attains Patent Issuance for DsiRNAs Directed at a Key Cancer Regulator, the KRAs Gene	142
Kyowa Hakko Kirin Selects Second DsiRNA Therapeutic Candidate for Development	143
SomaGenics Receives Patent for sshRNA Technology and Two New Small Business Innovation NIH Grants	143
Alnylam Attains Notice of Allowance from USPTO for New Patents from the Tuschl II Patent Estate including RNAi Therapeutics	143
Patent Allowance of Dicerna Claims Covering of Extended Dicer Substrate Therapeutic Structures	144
Carnegie and UMASS Receives Broad U.S. Patent for RNA Interference	144
InteRNA Technologies Granted Notice of Allowance for miRNA Sequences	144
US Patent Concerning RNAi Granted to Carnegie Institution and UMASS Medical School	145
Alnylam Receives Orphan Drug Designation from USFDA for ALN-TTR02	145
Sirnaomics Receives NIH SBIR Funds to Develop siRNA Therapeutics	145
Biosearch Technologies Releases Advanced RNA FISH Design Software	146
Phalanx Biotech Launches miRBase r18 based microRNA OneArray® Microarray	146
Firefly BioWorks Develops miRNA Detection Technology Using Funds from Private and Public Organizations	146
Alnylam Commences Phase I Clinical Study of ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) to Treat TTR-Mediated Amyloidosis (ATTR)	146
Tekmira Expands Product Pipeline With RNAi Therapy to Treat Alcohol Dependence	147
Altogen Biosystems Launches Pancreas-targeted siRNA In Vivo Transfection Kit	147
Tekmira Receives Key Patents Broadly Covering LNP Formulations and Mitigation of Immune Stimulation	148
Tekmira Initiates TKM-Ebola Phase I Clinical Trial	148
Benitec Biopharma and Medistem Technologies Announces Successful Stem Cell based Treatment for RA	148
Asuragen Launches miRInform® Pancreas Test for Detecting Cancer	149
Arrowhead Issued Patent covering siRNA Inhibitors of HIF-2a (EPAS1)	149
Innovative Method to Monitor RNAi Activity in Blood Samples Discovered at Alnylam	149
Alnylam Files Clinical Trial Application for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin to Treat Transthyretin-Mediated Amyloidosis	149
Dicerna Pharmaceuticals Announces Selection of First DsiRNA Therapeutic Candidate	149
USPTO Issues Patents for Lentiviral Vector and SMaRT RNA Platforms to VIRxSYS	150
Alnylam Pharmaceuticals Issues InterfeRx™ Intellectual Property License to Sylentis to Develop and Commercialize RNAi Therapeutics	150
Alnylam Expands "Alnylam 5x15" RNAi Therapeutic Pipeline with ALN-APC, an RNAi Therapeutic Targeting Protein C to Treat Hemophilia	151
Regulus Therapeutics Identifies Third microRNA Target to Trigger a Preclinical Milestone Payment from GSK	151
Life Technologies Generates Novel Drug Delivery Technology for Therapeutic Applications	151
LC Sciences Introduces V17 MicroRNA Microarrays	151
Benitec Limited Receives RNA Interference Patent in Japan	152
Tekmira Announces USPTO Issuance of Key Patents Covering LNP Manufacturing Process and Mitigation of siRNA immune stimulation	152
Bioo Scientific Introduces the new NEXTflex Small RNA Sequencing Kit for NGS Library Prep	152
Asuragen Introduces miRNA Biofluids Service	153
Affymetrix Introduces Next-Generation microRNA Solution GeneChip® miRNA 2.0 Array	153
New US Patent Issued to Silence Therapeutics Covering Fundamental RNA Interference Technology Presently in Several Clinical Trials	153
Cenix BioScience Receives Grant for R&D	154
Regulus Therapeutics Accredited with Federal Grant Awards for microRNA Therapeutics Designed for Fibrosis and Hepatitis C Viral Infection Treatment	154
RXi Pharmaceuticals Receives US$ 1 Million in IRS Grants to Improve RNAi Therapeutics	155
Life Technologies Introduces Advanced DNA and RNA Quantitation System	155
Tekmira Receives Key Patents covering LNP Manufacturing and Mitigation of siRNA Immune stimulation	155
Regulus Therapeutics Attains Supplementary Patents on microRNA Therapeutics for the Treatment of Hepatitis C Virus (HCV) Infection	156
Successful Grant of Further Hepatitis C RNAi Patent in the United States	156
Silence Therapeutics Receives New Patents Covering siRNA Sequences for RNA Interference Therapeutics	156
Promega Enhances Sensitivity for RNA Quantification with New GoTaq® 2-Step RT-qPCR	157
Marina Biotech Receives the US Patent for Amphoteric Liposomal siRNA Delivery Technology	157
Ocimum Biosolutions Provides Innovative Microrna Microarray Technology Solutions	158
Expansion of RNAi Structural Modification IP Portfolio Achieved Through Receipt of New U.S. Patent by Silence Therapeutics	158
RXi Pharmaceuticals Receives NIH Grant for Advancing RNAi Therapeutics	158
Affymetrix Launches QuantiGene® ViewRNA for In Situ Multiplex Gene Expression Analysis	159
Silence Therapeutics Announced the Issuance of New US Patent Broadly Covering Methods for Enhancing Silencing Activity of RNAi Therapeutics	159
Alnylam Secures Intellectual Property and Technology for RNAi Applications in Vaccine Research and Development	160
Benitec Limited Receives Hepatitis C RNA Interference Patent in the United States	160
Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States	161
Regulus Therapeutics Gains sole License for Intellectual Property to microRNA-21 for Heart, Liver, and Kidney Diseases	161
Kylin Therapeutics Granted pRNAi Technology Patent	161
Alnylam Granted Additional Tuschl II Patent in Japan	161
Regulus Therapeutics Obtains Exclusive License for Intellectual Property on Immuno-inflammatory microRNAs from the California Institute of Technology	162
Rosetta Genomics Receives Additional Patent	162
Bioo Scientific Unveils the patent pending T3™ Conjugation Kit for Targeted siRNA Delivery In Vivo	162
Thermo Fisher Scientific Initiates New Grant Scheme for RNAi Discovery	163
OPKO Health Issued US Patent Covering Use and Administration of Anti-HIF 1 Alpha siRNAs	163
Sigma-Aldrich Launches MISSION® esiRNA	163
Affymetrix in Association with Genisphere Launches Best-in-Class Solution for microRNA Expression Research	163
GeneCopoeia Launches GenomeWide MicroRNA (miRNA) Functional Analysis Tools	164
Promega Launches pmirGLO Dual-Luciferase miRNA Target Expression Vector for microRNA Study	164
Alnylam Acquires Nucleonics Patent Assets	165
USPTO Grants Core RNAi Patent to Silence Therapeutics	165
Calando Receives US Patent for CALAA-01	166
Alnylam Grants New InterfeRx™ Intellectual Property License to Calando	166
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Related to microRNA Antagonists for Treatment of Inflammatory Diseases	166
Open Biosystems Unveils Decode RNAi Viral Screening Pools	166
Calando Attains Chinese Patent Rights for Methods and Compositions for Therapeutic Use of RNA Interference	167
Thermo Fisher Scientific Launches a New RNA-Interference Technology	167
Alnylam Grants Shanghai GenePharma License to Kreutzer-Limmer Patents	167
Alnylam Granted New Patent Covering RNAi Therapeutics in the UK	168
Qiagen Launches RNA Purification Kit	168
RXi Pharmaceuticals Granted Australian Patent Application License	168
RXi Pharmaceuticals Signs License Agreement with TriLink Biotechnologies for RNA Chemistry Technologies	168
Sigma-Aldrich Introduces LentiExpress™ Technology for High-Throughput RNAi Screening	169
Rosetta Genomics is Issued a Second Patent for MicroRNAs	169
Rosetta Genomics Signs Collaboration Agreement with Ben Gurion University	169
US Government Signs $38.6 Million Contract with Alnylam	169
Open Biosystems Launches New shRNAmir Library for RNA Interference	170
Quark Pharmaceuticals Presents Positive Results in Pre-Clinical Studies of Systemic RNAi Compound in ARF	170
Alnylam and Medtronic Advance Collaboration on Drug-Device Combinations to Treat Neurodegenerative Diseases	171
Oligo PRO™ 24HT System for the Parallel Analysis of Oligonucleotide and RNAi Duplex Purity	171
Mirus Bio Discovers New Breakthrough Technology for RNAi Therapeutics	171
Kylin Therapeutics Signs License Agreement with Purdue University for RNAi Delivery Technology	172
Partnership Between Intradigm and Agilent to Develop RNA Interference Oncology Therapeutic	172
Alnylam Achieves Important Milestone in Collaborative Agreement	172
Launch of New RNAi Services Laboratory to Continue Research in Drug Discovery and Development	173
Alnylam Initiates New Research Program on RNAi Therapeutics	173
Alnylam Announces Advancement of New RNAi Therapeutic Development Program	173
Alnylam Grants License to Bio-Rad for Kreutzer-Limmer Patents in the RNAi Research Products Market	174
Luminex and Exiqon Jointly Produce New microRNAs Product Line	174
Mirus Bio Granted Broad RNAi Patent Using its Proprietary Hydrodynamic Intravascular Injection	175
Invitrogen Launches Advanced Transfection Reagents	175
Exiqon Establishes Sales Headquarters in the US	175
Mirus Bio Announces New Tool for Gene Function Analysis	175
Alnylam Grants Quark License to Develop and Commercialize RNAi Therapeutic Products	176
Exiqon Signs License Agreement with Max Planck Society for Diagnostic Use of Micro-RNAs	176
Abbott and Dharmacon Collaborate to Develop siRNA-Based Therapeutics	176
Acuity signs a pact with ZaBeCor for developing anti-inflammatory siRNA	177
Invitrogen Signs Agreement with genOway	177
Invitrogen Launches Stealth™ RNAi Human Kinase Collection	177
Novartis joins hands with Alnylam for RNAi Therapeutics Innovation	178
SB introduces Genome-Wide Human and Mouse siRNA Libraries	178
Analysis by Application	179
Exhibit 20. RNAi Applications – Global Market Estimations & Predictions (2005 -2020) by Type for Research, Therapeutics, Drug Development and Other in US$ Million	179
Exhibit 21. RNAi Applications - Global Market Shares (2010, 2015 & 2020) by Type for Research, Therapeutics, Drug Development and Other	180
Global Market for RNAi in Research	181
Exhibit 22. RNAi in Research - Global Market Estimations & Predictions (2005 - 2020) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other in US$ Million	181
Exhibit 23. RNAi in Research - Global Market Shares (2010, 2015 & 2020) by Application for Functional Genomics, Protein Chemistry, Metabolism and Other	182
Exhibit 24. RNAi in Research - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	183
Exhibit 25. RNAi in Research - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	184
Exhibit 26. List of Global Companies/Organizations in RNAi Research	184
North American Market for RNAi in Research	185
Exhibit 27. RNAi in Research – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	185
Exhibit 28. RNAi in Research – North American Market Shares (2010, 2015 & 2020) for United States and Canada	186
United States Market for RNAi in Research	186
Canadian Market for RNAi in Research	186
European Market for RNAi in Research	187
Exhibit 29. RNAi in Research - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	187
Exhibit 30. RNAi in Research - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	188
German Market for RNAi in Research	188
United Kingdom Market for RNAi in Research	188
Belgian Market for RNAi in Research	188
French Market for RNAi in Research	188
Russian Market for RNAi in Research	188
Asia-Pacific Market for RNAi in Research	189
Exhibit 31. RNAi in Research - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	189
Exhibit 32. RNAi in Research – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	190
Australian Market for RNAi in Research	190
Japanese Market for RNAi in Research	190
Chinese Market for RNAi in Research	190
Indian Market for RNAi in Research	190
South Korean Market for RNAi in Research	190
Rest of World Market for RNAi in Research	191
Exhibit 33. RNAi in Research – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	191
Exhibit 34. RNAi in Research – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	192
Brailian Market for RNAi in Research	192
Israelian Market for RNAi in Research	192
South African Market for RNAi in Research	192
RNAi in Functional Genomics	193
Global Market for RNAi in Functional Genomics	193
Exhibit 35. RNAi in Functional Genomics – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	193
Exhibit 36. RNAi in Functional Genomics – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	194
North American Market for RNAi in Functional Genomics	195
Exhibit 37. RNAi in Functional Genomics – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	195
Exhibit 38. RNAi in Functional Genomics – North American Market Shares (2010, 2015 & 2020) for United States and Canada	196
European Market for RNAi in Functional Genomics	197
Exhibit 39. RNAi in Functional Genomics- European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	197
Exhibit 40. RNAi in Functional Genomics - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	198
Asia-Pacific Market for RNAi in Functional Genomics	199
Exhibit 41. RNAi in Functional Genomics- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	199
Exhibit 42. RNAi in Functional Genomics – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	200
Rest of World Market for RNAi in Functional Genomics	201
Exhibit 43. RNAi in Functional Genomics – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	201
Exhibit 44. RNAi in Functional Genomics – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	202
RNAi in Protein Chemistry	203
Global Market for RNAi in Protein Chemistry	203
Exhibit 45. RNAi in Protein Chemistry– Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	203
Exhibit 46. RNAi in Protein Chemistry – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	204
North American Market for RNAi in Protein Chemistry	205
Exhibit 47. RNAi in Protein Chemistry – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	205
Exhibit 48. RNAi in Protein Chemistry – North American Market Shares (2010, 2015 & 2020) for United States and Canada	206
European Market for RNAi in Protein Chemistry	207
Exhibit 49. RNAi in Protein Chemistry - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	207
Exhibit 50. RNAi in Protein Chemistry - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	208
Asia-Pacific Market for RNAi in Protein Chemistry	209
Exhibit 51. RNAi in Protein Chemistry- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	209
Exhibit 52. RNAi in Protein Chemistry – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	210
Rest of World Market for RNAi in Protein Chemistry	211
Exhibit 53. RNAi in Protein Chemistry – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	211
Exhibit 54. RNAi in Protein Chemistry – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	212
RNAi in Metabolism	213
Global Market for RNAi in Metabolism	213
Exhibit 55. RNAi in Metabolism– Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	213
Exhibit 56. RNAi in Metabolism – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	214
North American Market for RNAi in Metabolism	215
Exhibit 57. RNAi in Metabolism – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	215
Exhibit 58. RNAi in Metabolism – North American Market Shares (2010, 2015 & 2020) for United States and Canada	216
European Market for RNAi in Metabolism	217
Exhibit 59. RNAi in Metabolism - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	217
Exhibit 60. RNAi in Metabolism - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	218
Asia-Pacific Market for RNAi in Metabolism	219
Exhibit 61. RNAi in Metabolism- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	219
Exhibit 62. RNAi in Metabolism – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	220
Rest of World Market for RNAi in Metabolism	221
Exhibit 63. RNAi in Metabolism – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	221
Exhibit 64. RNAi in Metabolism – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	222
RNAi in Other Research Applications	223
Global Market for RNAi in Other Research Applications	223
Exhibit 65. RNAi in Other Research Applications – Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	223
Exhibit 66. RNAi in Other Research Applications – Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	224
North American Market for RNAi in Other Research Applications	225
Exhibit 67. RNAi in Other Research Applications – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	225
Exhibit 68. RNAi in Other Research Applications – North American Market Shares (2010, 2015 & 2020) for United States and Canada	226
European Market for RNAi in Other Research Applications	227
Exhibit 69. RNAi in Other Research Applications - European Market Estimations & Predictions (2005 - 2020)by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	227
Exhibit 70. RNAi in Other Research Applications - European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	228
Asia-Pacific Market for RNAi in Other Research Applications	229
Exhibit 71. RNAi in Other Research Applications- Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	229
Exhibit 72. RNAi in Other Research Applications – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	230
Rest of World Market for RNAi in Other Research Applications	231
Exhibit 73. RNAi in Other Research Applications – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	231
Exhibit 74. RNAi in Other Research Applications – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	232
RNAi Therapeutics	233
Exhibit 75. RNAi Therapeutics - Global Market Estimations & Predictions (2005 - 2020) by Application for Ophthalmology, Virology, Neurology, Oncology and Other in US$ Million	233
Exhibit 76. RNAi Therapeutics - Global Market Shares (2010, 2015 & 2020) by Application for Ophthalmology, Virology, Neurology, Oncology and Other	234
Exhibit 77. List of Global RNAi based Therapeutics Companies/Organization	234
Exhibit 78. Drug Development Status of RNAi based Therapeutics	235
Global Market for RNAi Therapeutics	237
Exhibit 79. RNAi Therapeutics - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	237
Exhibit 80. RNAi Therapeutics - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	238
North American Market for RNAi Therapeutics	239
Exhibit 81. RNAi Therapeutics – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	239
Exhibit 82. RNAi Therapeutics – North American Market Shares (2010, 2015 & 2020) for United States and Canada	240
United States Market for RNAi Therapeutics	240
Canadian Market for RNAi Therapeutics	240
European Market for RNAi Therapeutics	241
Exhibit 83. RNAi Therapeutics -European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	241
Exhibit 84. RNAi Therapeutics – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	242
German Market for RNAi Therapeutics	242
United Kingdom Market for RNAi Therapeutics	242
Belgian Market for RNAi Therapeutics	242
French Market for RNAi Therapeutics	242
Russian Market for RNAi Therapeutics	242
Asia-Pacific Market for RNAi Therapeutics	243
Exhibit 85. RNAi Therapeutics - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	243
Exhibit 86. RNAi Therapeutics – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	244
Australian Market for RNAi Therapeutics	244
Japanese Market for RNAi Therapeutics	244
Chinese Market for RNAi Therapeutics	244
Indian Market for RNAi Therapeutics	244
South Korean Market for RNAi Therapeutics	244
Rest of World Market for RNAi Therapeutics	245
Exhibit 87. RNAi Therapeutics – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	245
Exhibit 88. RNAi Therapeutics – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	246
Brazilian RNAi Therapeutics Market	246
Israeli RNAi Therapeutics Market	246
South African RNAi Therapeutics Market	246
RNAi in Ophthalmology	247
Global Market for RNAi in Ophthalmology	247
Exhibit 89. RNAi in Ophthalmology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	247
Exhibit 90. RNAi in Ophthalmology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	248
North American Market for RNAi in Ophthalmology	249
Exhibit 91. RNAi in Ophthalmology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	249
Exhibit 92. RNAi in Ophthalmology – North American Market Shares (2010, 2015 & 2020) for United States and Canada	250
European Market for RNAi in Ophthalmology	251
Exhibit 93. RNAi in Ophthalmology - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	251
Exhibit 94. RNAi in Ophthalmology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	252
Asia-Pacific Market for RNAi in Ophthalmology	253
Exhibit 95. RNAi in Ophthalmology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	253
Exhibit 96. RNAi in Ophthalmology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	254
Rest of World Market for RNAi in Ophthalmology	255
Exhibit 97. RNAi in Ophthalmology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	255
Exhibit 98. RNAi in Ophthalmology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	256
RNAi in Virology	257
Global Market for RNAi in Virology	257
Exhibit 99. RNAi in Virology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	257
Exhibit 100. RNAi in Virology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	258
North American Market for RNAi in Virology	259
Exhibit 101. RNAi in Virology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	259
Exhibit 102. RNAi in Virology – North American Market Shares (2010, 2015 & 2020) for United States and Canada	260
European Market for RNAi in Virology	261
Exhibit 103. RNAi in Virology - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	261
Exhibit 104. RNAi in Virology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	262
Asia-Pacific Market for RNAi in Virology	263
Exhibit 105. RNAi in Virology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	263
Exhibit 106. RNAi in Virology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	264
Rest of World Market for RNAi in Virology	265
Exhibit 107. RNAi in Virology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	265
Exhibit 108. RNAi in Virology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	266
RNAi in Neurology	267
Global Market for RNAi in Neurology	267
Exhibit 109. RNAi in Neurology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	267
Exhibit 110. RNAi in Neurology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	268
North American Market for RNAi in Neurology	269
Exhibit 111. RNAi in Neurology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	269
Exhibit 112. RNAi in Neurology – North American Market Shares (2010, 2015 & 2020) for United States and Canada	270
European Market for RNAi in Neurology	271
Exhibit 113. RNAi in Neurology -European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	271
Exhibit 114. RNAi in Neurology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	272
Asia-Pacific Market for RNAi in Neurology	273
Exhibit 115. RNAi in Neurology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	273
Exhibit 116. RNAi in Neurology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	274
Rest of World Market for RNAi in Neurology	275
Exhibit 117. RNAi in Neurology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	275
Exhibit 118. RNAi in Neurology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	276
RNAi in Oncology	277
Global Market for RNAi in Oncology	277
Exhibit 119. RNAi in Oncology - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	277
Exhibit 120. RNAi in Oncology - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	278
North American Market for RNAi in Oncology	279
Exhibit 121. RNAi in Oncology – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	279
Exhibit 122. RNAi in Oncology – North American Market Shares (2010, 2015 & 2020) for United States and Canada	280
European Market for RNAi in Oncology	281
Exhibit 123. RNAi in Oncology - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	281
Exhibit 124. RNAi in Oncology – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	282
Asia-Pacific Market for RNAi in Oncology	283
Exhibit 125. RNAi in Oncology - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	283
Exhibit 126. RNAi in Oncology – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	284
Rest of World Market for RNAi in Oncology	285
Exhibit 127. RNAi in Oncology – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	285
Exhibit 128. RNAi in Oncology – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	286
Other RNAi Therapeutics	287
Global Market for Other RNAi Therapeutics	287
Exhibit 129. Other RNAi Therapeutics - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	287
Exhibit 130. Other RNAi Therapeutics - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	288
North American Market for Other RNAi Therapeutics	289
Exhibit 131. Other RNAi Therapeutics – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	289
Exhibit 132. Other RNAi Therapeutics – North American Market Shares (2010, 2015 & 2020) for United States and Canada	290
European Market for Other RNAi Therapeutics	291
Exhibit 133. Other RNAi Therapeutics - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	291
Exhibit 134. Other RNAi Therapeutics – European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	292
Asia-Pacific Market for Other RNAi Therapeutics	293
Exhibit 135. Other RNAi Therapeutics - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	293
Exhibit 136. Other RNAi Therapeutics – Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	294
Rest of World Market for Other RNAi Therapeutics	295
Exhibit 137. Other RNAi Therapeutics – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	295
Exhibit 138. Other RNAi Therapeutics – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	296
RNAi in Drug Development	297
Exhibit 139. RNAi in Drug Development - Global Market Estimations & Predictions (2005 - 2020) by Application for Target Validation, Target Identification, Drug Mechanism and Other in US$ Million	297
Exhibit 140. RNAi in Drug Development - Global Market Shares (2010, 2015 & 2020) by Application for Target Validation, Target Identification, Drug Mechanism and Other	298
Global Market for RNAi in Drug Development	299
Exhibit 141. RNAi in Drug Development - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	299
Exhibit 142. RNAi in Drug Development - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	300
North American Market for RNAi in Drug Development	301
Exhibit 143. RNAi in Drug Development – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	301
Exhibit 144. RNAi in Drug Development – North American Market Shares (2010, 2015 & 2020) for United States and Canada	302
United States RNAi in Drug Development Market	302
Canadian RNAi in Drug Development Market	302
European Market for RNAi in Drug Development	303
Exhibit 145. RNAi in Drug Development - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	303
Exhibit 146. RNAi in Drug Development– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	304
German RNAi in Drug Development Market	304
United Kingdom RNAi in Drug Development Market	304
Belgian RNAi in Drug Development Market	304
France RNAi in Drug Development Market	304
Russian RNAi in Drug Development Market	304
Asia-Pacific Market for RNAi in Drug Development	305
Exhibit 147. RNAi in Drug Development - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	305
Exhibit 148. RNAi in Drug Development– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	306
Australian RNAi in Drug Development Market	306
Japan RNAi in Drug Development Market	306
Chinese RNAi in Drug Development Market	306
India RNAi in Drug Development Market	306
South Korea RNAi in Drug Development Market	306
Rest of World Market for RNAi in Drug Development	307
Exhibit 149. RNAi in Drug Development – Rest of Wolrd Market Estimations & Predictions (2005 - 2020) by Country for Brazil , Israel, South Africa and Other Countries in US$ Million	307
Exhibit 150. RNAi in Drug Development – Rest of Wolrd Market Shares (2010, 2015 & 2020) by Country for Brazil , Israel, South Africa and Other Countries in US$ Million	308
Brazilian RNAi in Drug Development Market	308
Israel RNAi in Drug Development Market	308
South Africa RNAi in Drug Development Market	308
RNAi in Target Validation	309
Global Market for RNAi in Target Validation	309
Exhibit 151. RNAi in Target Validation - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	309
Exhibit 152. RNAi in Target Validation - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	310
North American Market for RNAi in Target Validation	311
Exhibit 153. RNAi in Target Validation – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	311
Exhibit 154. RNAi in Target Validation – North American Market Shares (2010, 2015 & 2020) for United States and Canada	312
European Market for RNAi in Target Validation	313
Exhibit 155. RNAi in Target Validation - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	313
Exhibit 156. RNAi in Target Validation– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	314
Asia-Pacific Market for RNAi in Target Validation	315
Exhibit 157. RNAi in Target Validation - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	315
Exhibit 158. RNAi in Target Validation– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	316
Rest of World Market for RNAi in Target Validation	317
Exhibit 159. RNAi in Target Validation – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries in US$ Million	317
Exhibit 160. RNAi in Target Validation – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries	318
RNAi in Target Identification	319
Global Market for RNAi in Target Identification	319
Exhibit 161. RNAi in Target Identification - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	319
Exhibit 162. RNAi in Target Identification - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	320
North American Market for RNAi in Target Identification	321
Exhibit 163. RNAi in Target Identification – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	321
Exhibit 164. RNAi in Target Identification – North American Market Shares (2010, 2015 & 2020) for United States and Canada	322
European Market for RNAi in Target Identification	323
Exhibit 165. RNAi in Target Identification - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	323
Exhibit 166. RNAi in Target Identification– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	324
Asia-Pacific Market for RNAi in Target Identification	325
Exhibit 167. RNAi in Target Identification - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	325
Exhibit 168. RNAi in Target Identification– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	326
Rest of World Market for RNAi in Target Identification	327
Exhibit 169. RNAi in Target Identification – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	327
Exhibit 170. RNAi in Target Identification – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	328
RNAi in Drug Mechanism	329
Global Market for RNAi in Drug Mechanism	329
Exhibit 171. RNAi in Drug Mechanism - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	329
Exhibit 172. RNAi in Drug Mechanism - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	330
North American Market for RNAi in Drug Mechanism	331
Exhibit 173. RNAi in Drug Metabolism – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	331
Exhibit 174. RNAi in Drug Metabolism – North American Market Shares (2010, 2015 & 2020) for United States and Canada	332
European Market for RNAi in Drug Mechanism	333
Exhibit 175. RNAi in Drug Mechanism - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	333
Exhibit 176. RNAi in Drug Mechanism– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	334
Asia-Pacific Market for RNAi in Drug Mechanism	335
Exhibit 177. RNAi in Drug Mechanism - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	335
Exhibit 178. RNAi in Drug Mechanism– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	336
Rest of World Market for RNAi in Drug Mechanism	337
Exhibit 179. RNAi in Drug Metabolism – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	337
Exhibit 180. RNAi in Drug Metabolism – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	338
RNAi in Other Drug Development Applications	339
Global Market for RNAi in Other Drug Development Applications	339
Exhibit 181. RNAi in Other Drug Development Applications - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	339
Exhibit 182. RNAi in Other Drug Development Applications - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	340
North American Market for RNAi in Other Drug Development Applications	341
Exhibit 183. RNAi in Other Drug Development Applications – North American Market Estimations & Predictions (2005 - 2020) for United States and Canada in US$ Million	341
Exhibit 184. RNAi in Other Drug Development Applications – North American Market Shares (2010, 2015 & 2020) for United States and Canada	342
European Market for RNAi in Other Drug Development Applications	343
Exhibit 185. RNAi in Other Drug Development Applications - European Market Estimations & Predictions (2005 - 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe in US$ Million	343
Exhibit 186. RNAi in Other Drug Development Applications– European Market Shares (2010, 2015 & 2020) by Country for Germany, United Kingdom, Belgium, France, Russia and Rest of Europe	344
Asia-Pacific Market for RNAi in Other Drug Development Applications	345
Exhibit 187. RNAi in Other Drug Development Applications - Asia-Pacific Market Estimations & Predictions (2005 - 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific in US$ Million	345
Exhibit 188. RNAi in Other Drug Development Applications– Asia-Pacific Market Shares (2010, 2015 & 2020) by Country for Australia, Japan, China, India, South Korea and Rest of Asia-Pacific	346
Rest of World Market for RNAi in Other Drug Development Applications	347
Exhibit 189. RNAi in Other Drug Development Applications – Rest of World Market Estimations & Predictions (2005 - 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	347
Exhibit 190. RNAi in Other Drug Development Applications – Rest of World Market Shares (2010, 2015 & 2020) for Brazil, Israel, South Africa and Other Countries US$ Million	348
Analysis by Tools/Products	349
Exhibit 191. RNAi Tools/Products – Global Market Estimations & Predictions (2005 - 2020) by Type for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other in US$ Million	349
Exhibit 192. RNAi Tools/Products – Global Market Shares (2010, 2015 & 2020) by Type for Design/Software, Synthesis, Delivery, Monitoring/Optimizing, Libraries and Other	350
RNAi Design/Software Market	351
Exhibit 193. RNAi Design/Software Tools/Products - Global Market Estimations & Predictions (2005 - 2020) by Type for MiRNA Target Scan, MiRNA Analysis Software, Design Algorithm and Other in US$ Million	351
Exhibit 194. RNAi Design/Software Tools/Products - Global Market Shares (2010, 2015 & 2020) by Type for MiRNA Target Scan, MiRNA Analysis Software, Design Algorithm and Other	352
Global RNAi Design/Software Market	353
Exhibit 195. RNAi Design/Software - Global Market Estimations & Predictions (2005 - 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World in US$ Million	353
Exhibit 196. RNAi Design/Software - Global Market Shares (2010, 2015 & 2020) by Geographic Region for North America, Europe, Asia-Pacific and Rest of World	354
North American RNAi Design/Software Market	355
Exhibit 197. RNAi Design/Software – North American Market Estimations & Predictions (2005 - 2020) for United States

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $4680
Multi User - US $9500
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify